Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Main focus: Novel stem cell-derived cellular therapies
Company stage: Pre-clinical
Genome editing tool: Undisclosed
Funding stage: Private
Location: Cambridge, MA, USA
Clade Therapeutics is focused on the development of next-generation cellular therapies, applying its induced pluripotent stem cell (iPSC)-based platform. Using its technology, it is able to generate iPSC-derived adult T, natural killer (NK) and B cells. The company is co-founded by Chad Cowan, a CRISPR Therapeutics co-founder, however, exactly how gene editing is used in the cell therapies under development has not yet been undisclosed.